We’re excited to share that Cognite NeurotechnologyTM has joined the second cohort of Surrey Venture Studio.
The programme will support us as we continue developing NeuroLeapTM and take the next steps towards bringing personalised neurotechnology into real-world ADHD care.
Over the coming months, we’re particularly looking forward to working closely with patients, clinicians and healthcare organisations to better understand their needs, gather feedback on our product and strengthen our route to market.
It’s a great opportunity to build on our progress so far, test our assumptions and make sure NeuroLeapTM is being developed with the people who may ultimately use, recommend and deliver it.
We’re excited to get started and meet the other participants.
